July 08, 2024
2 min watch
Save
VIDEO: CYCLONE 2 probes abemaciclib and abiraterone in prostate cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CYCLONE 2 study into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.
Chehrazi-Raffle, a medical oncologist at the City of Hope Duarte Cancer Center, highlighted the study, which looked at a combination therapy of abemaciclib (Verzenio, Eli Lilly & Co.) and abiraterone in a sample of patients.
“We'll have to wait for CYCLONE 3 to see if this combination has any value in the high-risk, hormone-sensitive setting. But given the results of CYCLONE 2, I don't anticipate there'll be new signals of efficacy,” Chehrazi-Raffle said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Chehrazi-Raffle reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.